Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer
Science Advances, 2016; 2(6):e1501924

2016 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Originally published at:
http://doi.org/10.1126/sciadv.1501924
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer


Science
Volume 2(6):e1501924
June 24, 2016
Fig. 1 Genomic agonism and phenotypic antagonism between ER and PR in breast cancer.


Published by AAAS
Fig. 2 PR redirects ER binding to sites correlated with the binding of PR and ER/PR complexes.


Published by AAAS
Fig. 3 Progestin stimulation remodels nucleosomes to redirect ER binding to enhancers and binding sites enriched for BRCA1.

Fig. 4 Presence and activity of PR contribute to the prognostic value of ER.

Fig. 5 Cytotoxic tumor regression on combination therapy with tamoxifen and PR antagonist CDB4124.